Exhibit
99.1
Vivos
Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update
Revenue
rises 24% quarter over quarter as Third quarter operating loss improves 18% year over year on cost reductions; Company regained compliance
with Nasdaq stockholders’ equity requirement
Management
to Host Conference Call today at 5:00 pm ET
LITTLETON,
Colo., November 16, 2026
– Vivos Therapeutics, Inc. (“Vivos” or the “Company’’)
(NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic
and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep related breathing disorders,
today reported financial results and operating highlights for the three and nine months ended September 30, 2026.
Kirk
Huntsman, Vivos’ Chairman and Chief Executive Officer, stated, “During the third quarter of 2026, we took decisive steps
to reduce costs and strengthen our balance sheet. Our operating loss improved 18% compared to the prior-year quarter, general and administrative
and sales and marketing expenses together declined by $1.6 million, and we have now eliminated an estimated $5 million or more in annual
operating costs, with further efficiencies underway. We also exchanged approximately $6.1 million of senior secured debt for equity during
2026 and, following the closing of our SOD Sciences transaction in October, regained compliance with Nasdaq’s stockholders’
equity requirement.”
Mr.
Huntsman continued, “We are also pursuing a number of clinical initiatives at our SCN and SAMC centers, including EEG testing and
treatment for insomnia and other non-OSA sleep disorders, the distribution and set-up of PAP and CPAP treatments, and remote patient
monitoring of CPAP users, together with the renegotiation of our payer contracts. We expect these initiatives to contribute to revenue
and margins beginning in the fourth quarter of 2026 and increasingly throughout 2027.”
Third
Quarter 2026 Financial and Operating Summary
| |
● |
Revenue
was $6.4 million for the third quarter of 2026, up 24% from $5.2 million in the second quarter of 2026, and $16.7 million for the
nine months ended September 30, 2026, compared to $6.8 million and $13.6 million for the three and nine months ended September 30,
2025. Third quarter service revenue increased 1% to $4.6 million, while product revenue decreased to $1.8 million from $2.2 million,
reflecting our strategic pivot away from appliance sales to dentists in our Vivos Integrated Provider (VIP) program. For the nine
months, service revenue increased 57% to $12.1 million, primarily attributable to sleep testing and resulting treatment services
in our Nevada operations; |
| |
|
|
| |
● |
Gross
profit was $3.3 million for the third quarter of 2026 and $9.3 million for the nine months ended September 30, 2026, compared to
$3.9 million and $7.6 million for the comparable periods in 2025. The third quarter decrease was due to lower product revenue and
higher cost of sales, while the nine-month increase was due to stronger service revenue; |
| |
|
|
| |
● |
Gross
margin was 52% in the third quarter of 2026 compared to 58% in the third quarter of 2025, due to the decrease in product revenue.
For the nine months ended September 30, 2026, gross margin was 56% compared to 55% in the same period in 2025; |
| |
|
|
| |
● |
Operating
expenses for the third quarter ended September 30, 2026 were $7.2 million, a 17% decrease compared to $8.7 million in the same period
a year ago, reflecting a $1.4 million reduction in general and administrative expenses, driven primarily by lower professional fees,
equipment maintenance and office expenses, as well as lower sales and marketing expenses. For the nine months ended September 30,
2026, operating expenses were $24.7 million versus $21.1 million in the same period in 2025, an increase driven primarily by the
costs of establishing our two Sleep and Airway Medicine Centers in Las Vegas and Henderson, Nevada; |
| |
● |
The
third quarter 2026 operating loss improved 18% to $3.9 million, compared to $4.7 million in the third quarter of 2025. For the nine months
ended September 30, 2026, the operating loss was $15.3 million compared to $13.5 million for the nine months ended September 30, 2025. |
| |
|
|
| |
● |
Net loss for the third quarter of 2026 was $2.0 million, compared to $5.4
million in the third quarter of 2025, and included approximately $2.9 million of other income from the reversal of our previously recorded
Employee Retention Credit liability; |
| |
|
|
| |
● |
At
September 30, 2026, cash and cash equivalents were $0.2 million and total stockholders’ equity was $2.4 million, compared to
cash and cash equivalents of $2.0 million and a stockholders’ deficit of $1.5 million as of December 31, 2025. Total liabilities
decreased to $20.7 million at September 30, 2026 from $26.7 million at December 31, 2025. Subsequent to quarter end, on October 16,
2026, we completed our SOD Sciences transaction, and on October 20, 2026, Nasdaq notified us that we had regained compliance with
its minimum stockholders’ equity requirement, subject to Nasdaq’s continued monitoring. |
Investor
Call and 10-Q Filing
Vivos
encourages investors and other interested parties to join its conference call today at 5:00 p.m. Eastern time. Management will discuss
further details on topics including Vivos’ strategic initiatives and their anticipated effect on near-term revenue growth and cash
burn.
To
access Vivos’ investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will
be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The
Access ID for the replay is 1177865. The replay will be available until Monday, November 30, 2026.
A
live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations. An online
archive of the webcast will be available at Vivos’ website for 30 days following the call.
In
addition, further information on Vivos’ financial results is included on the attached unaudited condensed consolidated balance
sheets and statements of operations, and additional information about Vivos’ financial performance is provided in Vivos’
Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2026, which has been filed with the Securities and Exchange
Commission (“SEC”). This press release discusses certain financial information for the second quarter ended June 30, 2026,
and more information about our results for the second quarter are included in Vivos’ Quarterly Report on Form 10-Q for the three
and six months ended June 30, 2026, which has been filed with the SEC. The full 10-Q reports will be available on the SEC Filings section
of the Investor Relations section of Vivos’ website at https://vivos.com/investor-relations.
About
Vivos Therapeutics, Inc.
Vivos
Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative
diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities
such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration
(FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’
groundbreaking Complete Airway Repositioning and Expansion (CARE) devices were the first oral appliances to receive FDA 510(k)
clearance for treating severe OSA in adults and the flagship DNA appliance is the first oral appliance to receive FDA clearance for treating
moderate to severe OSA in children.
OSA
and insomnia affect over 1 billion adults aged 30-69 years old worldwide, yet 80% or more remain undiagnosed and unaware of their condition.
These chronic disorders are not just a sleep issue - they are closely linked to many serious chronic health conditions. While the medical
community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood.
As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes. Vivos CARE oral medical devices
target the underlying physiology and anatomical deficiencies that are often associated with OSA.
Through
innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering
healthcare providers to address the complex needs of OSA patients more thoroughly.
Vivos
calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective
solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.
For
more information, visit www.vivos.com.
Cautionary
Note Regarding Forward-Looking Statements
This
press release, the conference call referred to herein, and statements of the Company’s management made in connection therewith
contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995) concerning future events.
Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”,
“believes”, “anticipates”, “hopes”, “estimates”, “goal”, “will”,
“would”, “could”, “potential”, “continue” and variations of such words and similar expressions
are intended to identify forward-looking statements.
These
statements involve significant known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject
to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the actual benefits
of the cost reductions, clinical initiatives and other matters described herein and actual revenue and cash flow results) may differ
materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results
to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing
strategies and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using
Vivos products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the
risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all, or maintain its Nasdaq listing
due to, among other things, its ability to meet Nasdaq’s stockholders’ equity and minimum bid price requirements; (v) the
risk that Vivos will not have enough cash to fund its operations and continue as a going concern; (vi) the risk that the final accounting
for the SOD Sciences transaction, or review by Nasdaq or Vivos’ independent registered public accounting firm, results in a smaller
increase in stockholders’ equity than expected; (vii) the risk that Vivos will not regain compliance with Nasdaq’s minimum
bid price requirement by December 2, 2026 or any extended deadline, or that stockholders will not approve the proposed reverse stock
split, or that the closing bid price of Vivos’ common stock will be $0.10 or less for ten consecutive business days, which would
result in a Nasdaq delisting determination and suspension of trading without any compliance period; (viii) the risk that the cost reductions
described in this press release will not produce the expected savings; (ix) the risk that Vivos’ new clinical initiatives and payer
contract renegotiations will not increase revenue or margins when expected, or at all, including because of reimbursement, licensing
or other regulatory requirements; (x) dilution from the conversion of outstanding preferred stock; (xi) market and other conditions;
and (xii) the other risk factors described in Vivos’ filings with the SEC, including under “Risk Factors” in its Annual
Report on Form 10-K for the year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.
Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov.
Except
to the extent required by law, Vivos expressly disclaims any obligation or undertaking to release publicly any updates or revisions to
any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change
in events, conditions, or circumstances on which any such statement is based.
Vivos
Investor Relations Contact:
Jennifer
Hauser, Executive Assistant to the CEO
jhauser@vivoslife.com
720-927-3125
-Financial
Tables Follow-
VIVOS
THERAPEUTICS INC.
Unaudited
Condensed Consolidated Statements of Operations
(In
Thousands, Except Per Share Amounts)
| | |
Three
Months Ended September 30, | | |
Nine
Months Ended September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Revenue | |
| | | |
| | | |
| | | |
| | |
| Product revenue | |
$ | 1,772 | | |
$ | 2,195 | | |
$ | 4,567 | | |
$ | 5,893 | |
| Service
revenue | |
| 4,642 | | |
| 4,588 | | |
| 12,141 | | |
| 7,726 | |
| Total revenue | |
| 6,414 | | |
| 6,783 | | |
| 16,708 | | |
| 13,619 | |
| | |
| | | |
| | | |
| | | |
| | |
| Cost
of sales (exclusive of depreciation and amortization shown separately below) | |
| 3,100 | | |
| 2,846 | | |
| 7,382 | | |
| 6,065 | |
| | |
| | | |
| | | |
| | | |
| | |
| Gross
profit | |
| 3,314 | | |
| 3,937 | | |
| 9,326 | | |
| 7,554 | |
| | |
| | | |
| | | |
| | | |
| | |
| Operating expenses | |
| | | |
| | | |
| | | |
| | |
| General and administrative | |
| 6,450 | | |
| 7,884 | | |
| 22,533 | | |
| 19,181 | |
| Sales and marketing | |
| 210 | | |
| 403 | | |
| 614 | | |
| 1,018 | |
| Depreciation
and amortization | |
| 550 | | |
| 384 | | |
| 1,515 | | |
| 867 | |
| | |
| | | |
| | | |
| | | |
| | |
| Total
operating expenses | |
| 7,210 | | |
| 8,671 | | |
| 24,662 | | |
| 21,066 | |
| | |
| | | |
| | | |
| | | |
| | |
| Operating loss | |
| (3,896 | ) | |
| (4,734 | ) | |
| (15,336 | ) | |
| (13,512 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Non-operating income (expense) | |
| | | |
| | | |
| | | |
| | |
| Other expense | |
| (981 | ) | |
| (679 | ) | |
| (3,199 | ) | |
| (850 | ) |
| Other
income | |
| 2,906 | | |
| 13 | | |
| 3,290 | | |
| 86 | |
| Loss before income taxes | |
| (1,971 | ) | |
| (5,400 | ) | |
| (15,245 | ) | |
| (14,276 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net
loss | |
$ | (1,971 | ) | |
$ | (5,400 | ) | |
$ | (15,245 | ) | |
$ | (14,276 | ) |
| Net loss attributable
to non-controlling interest | |
| (26 | ) | |
| - | | |
| (137 | ) | |
| - | |
| Net
loss attributable to stockholders | |
$ | (1,945 | ) | |
$ | (5,400 | ) | |
$ | (15,108 | ) | |
$ | (14,276 | ) |
| Net loss per share (basic
and diluted) | |
$ | (0.07 | ) | |
$ | (0.49 | ) | |
$ | (0.77 | ) | |
$ | (1.49 | ) |
| Weighted average number
of shares of Common Stock outstanding (basic and diluted) | |
| 26,528,253 | | |
| 10,963,590 | | |
| 19,658,339 | | |
| 9,557,368 | |
See
the notes to the unaudited condensed consolidated financial statements in Vivos’ Quarterly Report on Form 10-Q for the quarter
ended September 30, 2026.
VIVOS
THERAPEUTICS INC.
Unaudited
Condensed Consolidated Balance Sheets
(In
Thousands, Except Per Share Amounts)
| | |
September
30, 2026 | | |
December
31, 2025 | |
| Current assets | |
| | | |
| | |
| Cash and cash
equivalents | |
$ | 247 | | |
$ | 2,029 | |
| Accounts receivable, net
of allowance of $1,250 and $882, respectively | |
| 2,370 | | |
| 1,581 | |
| Prepaid
expenses and other current assets | |
| 891 | | |
| 774 | |
| | |
| | | |
| | |
| Total current assets | |
| 3,508 | | |
| 4,384 | |
| | |
| | | |
| | |
| Long-term assets | |
| | | |
| | |
| Goodwill | |
| 8,572 | | |
| 8,572 | |
| Property and equipment,
net | |
| 3,347 | | |
| 3,757 | |
| Operating lease right-of-use
asset | |
| 3,624 | | |
| 4,166 | |
| Intangible assets, net | |
| 3,438 | | |
| 4,045 | |
| Deposits
and other | |
| 367 | | |
| 228 | |
| | |
| | | |
| | |
| Total
assets | |
$ | 22,856 | | |
$ | 25,152 | |
| | |
| | | |
| | |
| LIABILITIES AND STOCKHOLDERS’
EQUITY/(DEFICIT) | |
| | | |
| | |
| Current liabilities | |
| | | |
| | |
| Accounts payable | |
$ | 2,739 | | |
$ | 1,679 | |
| Accrued expenses | |
| 8,819 | | |
| 5,988 | |
| Contract liabilities | |
| 72 | | |
| 479 | |
| Current portion of operating
lease liability | |
| 850 | | |
| 672 | |
| Current portion of financing
lease liability | |
| 57 | | |
| 55 | |
| Current portion of debt | |
| 1,502 | | |
| 8,353 | |
| Other
current liabilities | |
| 2,124 | | |
| 850 | |
| | |
| | | |
| | |
| Total current liabilities | |
| 16,163 | | |
| 18,076 | |
| | |
| | | |
| | |
| Long-term liabilities | |
| | | |
| | |
| Employee retention credit
liability | |
| - | | |
| 2,904 | |
| Operating lease liability,
net of current portion | |
| 3,198 | | |
| 3,840 | |
| Financing lease liability,
net of current portion | |
| 69 | | |
| 113 | |
| Debt, net of current portion | |
| 313 | | |
| 469 | |
| Other
liabilities | |
| 950 | | |
| 1,300 | |
| | |
| | | |
| | |
| Total
liabilities | |
| 20,693 | | |
| 26,702 | |
| | |
| | | |
| | |
| Commitments and contingencies | |
| - | | |
| - | |
| | |
| | | |
| | |
| Stockholders’ equity/(deficit) | |
| | | |
| | |
| Preferred Stock, $0.0001 par value per share.
Authorized 50,000,000 shares; 3,610,995 shares issued and outstanding | |
$ | - | | |
$ | - | |
| Preferred Stock –
additional paid in capital | |
| 3,605 | | |
| - | |
| Common Stock, $0.0001 par value per share.
Authorized 200,000,000 shares; issued and outstanding 33,820,768 shares as of September 30, 2026 and 9,286,609 shares as of December
31, 2025 | |
| 3 | | |
| 1 | |
| Additional paid-in capital | |
| 139,217 | | |
| 123,866 | |
| Accumulated
deficit | |
| (140,465 | ) | |
| (125,357 | ) |
| Total
stockholders’ equity/(deficit) | |
| 2,360 | | |
| (1,490 | ) |
| | |
| | | |
| | |
| Non-controlling
interest | |
| (197 | ) | |
| (60 | ) |
| Total
equity/(deficit) | |
| 2,163 | | |
| (1,550 | ) |
| | |
| | | |
| | |
| Total
liabilities and equity/(deficit) | |
$ | 22,856 | | |
$ | 25,152 | |
See
the notes to the unaudited condensed consolidated financial statements in Vivos’ Quarterly Report on Form 10-Q for the quarter
ended September 30, 2026.